WALTHAM, Mass., May 22, 2024 Repligen Corporation , a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at the following June.
Reports fourth quarter revenue of $156 million and full year revenue of $639 millionContinued strength in orders with fourth quarter book-to-bill ratio of 1.03
WALTHAM, Mass., Dec. 07, 2023 Repligen Corporation today announced that on December 6, 2023, it entered into privately negotiated exchange and/or subscription agreements with certain holders of.